Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · IEX Real-Time Price · USD
2.520
-0.110 (-4.18%)
At close: Jul 19, 2024, 4:00 PM
2.640
+0.120 (4.76%)
Pre-market: Jul 22, 2024, 7:40 AM EDT
Cellectar Biosciences Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CLRB stock have an average target of 20, with a low estimate of 12 and a high estimate of 28. The average target predicts an increase of 693.65% from the current stock price of 2.52.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2024.
Analyst Ratings
The average analyst rating for CLRB stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Roth MKM | Roth MKM | Strong Buy Maintains $20 → $28 | Strong Buy | Maintains | $20 → $28 | +1,011.11% | Mar 28, 2024 |
Oppenheimer | Oppenheimer | Buy Reiterates $11 → $12 | Buy | Reiterates | $11 → $12 | +376.19% | Mar 28, 2024 |
Roth MKM | Roth MKM | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +693.65% | Mar 4, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $4 | Strong Buy | Maintains | $3 → $4 | +58.73% | Nov 4, 2022 |
Oppenheimer | Oppenheimer | Buy Initiates $55 | Buy | Initiates | $55 | +2,082.54% | Jul 18, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
55.23M
EPS This Year
-1.90
from -3.11
EPS Next Year
-0.66
from -1.90
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | 124.3M | 194.9M | 323.5M | 408.3M |
Avg | n/a | 55.2M | 105.9M | 184.3M | 268.8M |
Low | n/a | 19.7M | 51.2M | 105.6M | 175.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | 252.9% | 205.4% | 121.6% |
Avg | - | - | 91.8% | 74.0% | 45.9% |
Low | - | - | -7.2% | -0.3% | -5.0% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.93 | 0.55 | 1.02 | 2.10 | 2.77 |
Avg | -1.90 | -0.66 | 0.22 | 1.20 | 2.26 |
Low | -1.85 | -1.27 | -0.35 | 0.40 | 1.52 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | 850.2% | 131.6% |
Avg | - | - | - | 441.5% | 89.2% |
Low | - | - | - | 81.8% | 26.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.